Evofem Biosciences, Inc.EVFMOTCMARKET
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank22
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P22
Within normal range
vs 5Y Ago
-0.6x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | -37.00% |
| Q2 2025 | -85.18% |
| Q1 2025 | 675.81% |
| Q4 2024 | 95.48% |
| Q3 2024 | 22.96% |
| Q2 2024 | -54.55% |
| Q1 2024 | -57.05% |
| Q4 2023 | 139.69% |
| Q3 2023 | 151.97% |
| Q2 2023 | -22.37% |
| Q1 2023 | -74.12% |
| Q4 2022 | -77.00% |
| Q3 2022 | -34.67% |
| Q2 2022 | -26.98% |
| Q1 2022 | 29.81% |
| Q4 2021 | -0.85% |
| Q3 2021 | 2.38% |
| Q2 2021 | 8.59% |
| Q1 2021 | 22.13% |
| Q4 2020 | 41.00% |
| Q3 2020 | 59.73% |
| Q2 2020 | -37.84% |
| Q1 2020 | 23.75% |
| Q4 2019 | -39.40% |
| Q3 2019 | 7.95% |
| Q2 2019 | -33.50% |
| Q1 2019 | -19.27% |
| Q4 2018 | -0.80% |
| Q3 2018 | -16.75% |
| Q2 2018 | -1.05% |
| Q1 2018 | 3287.85% |
| Q4 2017 | -27.49% |
| Q3 2017 | -68.71% |
| Q2 2017 | 0.39% |
| Q1 2017 | 67.51% |
| Q4 2016 | -4.11% |
| Q3 2016 | 0.00% |